Baillie Gifford & Co
MYGN icon

Baillie Gifford & Co’s Myriad Genetics MYGN Stock Holding History

Baillie Gifford & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,970,006
Closed -$128M – 247
2020
Q1 		$128M Buy
8,970,006
+4,828
+0.1% +$102K 0.14% 92
2019
Q4 		$244M Sell
8,965,178
-278,625
-3% -$7.67M 0.24% 83
2019
Q3 		$265M Sell
9,243,803
-283,339
-3% -$8.26M 0.3% 74
2019
Q2 		$265M Sell
9,527,142
-13,444
-0.1% -$380K 0.28% 75
2019
Q1 		$317M Buy
9,540,586
+55,642
+0.6% +$1.69M 0.35% 67
2018
Q4 		$276M Sell
9,484,944
-62,249
-0.7% -$2.24M 0.36% 64
2018
Q3 		$439M Buy
9,547,193
+92,008
+1% +$4.09M 0.47% 53
2018
Q2 		$353M Sell
9,455,185
-107,778
-1% -$3.64M 0.38% 56
2018
Q1 		$283M Sell
9,562,963
-62,883
-0.7% -$2.13M 0.33% 60
2017
Q4 		$331M Buy
9,625,846
+15,309
+0.2% +$516K 0.41% 57
2017
Q3 		$348M Sell
9,610,537
-54,710
-0.6% -$1.56M 0.44% 52
2017
Q2 		$250M Sell
9,665,247
-257,206
-3% -$5.46M 0.34% 62
2017
Q1 		$191M Sell
9,922,453
-237,305
-2% -$4.2M 0.28% 72
2016
Q4 		$169M Sell
10,159,758
-290,064
-3% -$5.25M 0.28% 69
2016
Q3 		$215M Sell
10,449,822
-871,476
-8% -$22.1M 0.34% 62
2016
Q2 		$346M Sell
11,321,298
-45,738
-0.4% -$1.59M 0.62% 44
2016
Q1 		$425M Buy
11,367,036
+50,708
+0.4% +$1.91M 0.75% 34
2015
Q4 		$488M Buy
11,316,328
+629,570
+6% +$26.6M 0.85% 32
2015
Q3 		$401M Buy
10,686,758
+311,000
+3% +$11M 0.78% 38
2015
Q2 		$353M Buy
10,375,758
+448,399
+5% +$15.2M 0.63% 43
2015
Q1 		$351M Buy
9,927,359
+268,356
+3% +$9.6M 0.67% 43
2014
Q4 		$329M Buy
9,659,003
+675,100
+8% +$24M 0.66% 44
2014
Q3 		$347M Buy
8,983,903
+198,400
+2% +$7.4M 0.76% 38
2014
Q2 		$342M Buy
8,785,503
+118,400
+1% +$4.41M 0.74% 37
2014
Q1 		$296M Buy
8,667,103
+4,118,403
+91% +$128M 0.7% 44
2013
Q4 		$95.4M Buy
4,548,700
+885,300
+24% +$22.4M 0.23% 73
2013
Q3 		$86.1M Buy
+3,663,400
New +$104M 0.22% 75

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Baillie Gifford & Co's MYGN Position: Q2 2020 in Review

Baillie Gifford & Co sold out of Myriad Genetics (MYGN) in Q2 2020, closing a stake of 8,970,006 shares — an estimated $128M sold.

Baillie Gifford & Co first reported a position in MYGN in Q3 2013 and held it in 27 quarters. The position peaked at $488M in Q4 2015. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2020.

  • Baillie Gifford & Co reported no remaining Myriad Genetics position as of Q2 2020 after selling out during the quarter.
  • Baillie Gifford & Co sold 8,970,006 Myriad Genetics shares in Q2 2020, an estimated $128M.
  • Baillie Gifford & Co first reported a position in Myriad Genetics in Q3 2013 and held it in 27 quarters.
  • Baillie Gifford & Co's Myriad Genetics position peaked at $488M in Q4 2015.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2020.

Based on Baillie Gifford & Co's 13F filing for Q2 2020, filed 12 Aug 2020.